Health & Biotech Copy RSS link Link copied to clipboard!
Experts call for rethinking chemoprophylaxis strategies for leprosy control
Global leprosy prevalence has plateaued since 2000, prompting a re-evaluation of chemoprophylaxis strategies. Trials like COLEP and PEOPLE showed limited long-term protection from single-dose rifampicin (SDR) and double-dose rifampicin (SDDR), with efficacy waning after two years. Concerns include rising rifampicin resistance, ethical issues regarding stigmatisation and drug exposure, and poor cost-effectiveness, particularly for high-risk household contacts. Emerging data suggests a paradoxical rise in disabilities following SDR campaigns. Experts recommend redirecting resources toward early case detection, treatment adherence, and systematic contact tracing rather than mass prophylaxis.
Microneedle biosensor detects impaired kidney drug clearance in rats
Sam Emaminejad and colleagues developed a minimally invasive microneedle biosensor capable of real-time assessment of liver and kidney drug clearance. Tested in a rat model, the device correlated interstitial fluid measurements with blood-equivalent pharmacokinetic parameters. The sensor successfully detected prolonged drug half-life in rats with liver damage and lower drug clearance in rats with adenine-induced kidney injury. Notably, the biosensor identified decreases in drug clearance before blood creatinine levels increased, indicating early detection of kidney function decline.
Syngene International reports strong sequential revenue growth amid profitability challenges
Syngene International Ltd reported a 13% sequential revenue increase in Q4 2026, driven by underlying business momentum and a new Antibody-Drug Conjugate Discovery Laboratory. However, year-on-year top-line growth was muted at 3% due to Librela destocking, while operating EBITDA margins fell to 29% from 34%. Profit after tax declined 16% year-on-year. The company expects flat performance for FY27 due to geopolitical uncertainties and ongoing Librela impacts, though it maintains a long-term partnership with Bristol-Myers Squibb until 2035.
Scientists develop mRNA therapy using red blood cells to attack tumours
Researchers at the Westlake Laboratory of Life Sciences and Biomedicine developed an innovative mRNA therapy platform called mRNA-LNP-Ery. This technology uses red blood cells to deliver genetic instructions directly into the body, transforming myeloid cells into cancer-fighting agents without the need for laboratory extraction. Preclinical animal models demonstrated strong antitumor activity, with the reprogrammed cells successfully migrating to tumours, eliminating cancer cells, and enhancing broader immune responses. The findings, published in Science Translational Medicine, suggest this approach could offer a scalable and cost-effective alternative to traditional CAR-T cell therapies.
Portable MiniDock MTB device enables rapid tuberculosis testing in under 30 minutes
Researchers from the University of California San Francisco and University of California Irvine demonstrated that the MiniDock MTB portable device delivers accurate tuberculosis diagnosis results in under 30 minutes at the point of care. The device matches standard laboratory accuracy while using alternative samples like tongue swabs, benefiting children and HIV patients. It utilizes molecular technology similar to COVID-19 diagnostics, runs on battery power, and requires minimal training. The World Health Organization has issued its first recommendation for this test type, potentially enabling same-day diagnosis and treatment globally.
4DMedical shares rise 1173% in a year due to US regulatory clearance
4DMedical Ltd shares have increased by 1,173% over the past 12 months, outperforming the broader ASX 200 healthcare sector which has fallen 39%. The growth is attributed to the company securing FDA 510(k) clearance for its CT:VQ platform in September 2025 and a one-year contract with GlaxoSmithKline starting in May 2026. Unlike peers facing regulatory uncertainty and currency challenges, 4DMedical has established a foothold in the US market and recently received certification in the United Kingdom. The company's software-as-a-service technology transforms routine chest CT scans without the need for contrast agents.
Bayer sues vaccine makers over alleged stolen technology
Bayer is suing pharmaceutical companies including Pfizer, Moderna, and Johnson & Johnson over alleged patent appropriation regarding mRNA stabilizing technology. The lawsuit claims the technology was originally developed by Monsanto, which Bayer acquired in 2018. Bayer states it did not share in the profits from the COVID-19 vaccines and seeks to recoup costs related to the acquisition and ongoing legal challenges regarding its herbicide Roundup.
Dognosis study finds dogs detect multiple cancers from breath with over 90 per cent accuracy
A study published in the Journal of Clinical Oncology reveals that trained dogs can detect multiple types of cancer from human breath samples with over 90 per cent accuracy, including early-stage cases. Conducted across six hospitals in India involving 1,502 participants, the research highlights the potential of combining canine olfaction with Bayesian modeling for non-invasive screening. Dognosis, the Indian startup behind the technology, aims to commercialise the system next year following further real-world validation. While results are promising, experts caution that established diagnostic tools remain necessary.
Eli Lilly reports strong growth potential amidst regulatory challenges in 10-Q filing
On May 01, 2026, Eli Lilly and Co released its 10-Q filing for the quarter ending March 31, 2026. Revenue increased driven by higher volumes of cardiometabolic products Mounjaro and Zepbound, which accounted for 65% of total revenue. The company received FDA Breakthrough Therapy designation for sofetabart mipitecan for ovarian cancer. While the GF Score is 95/100 indicating strong potential, the company faces regulatory litigation regarding the 340B program and pricing pressures. The stock trades at $934.60, undervalued by 28.3% relative to a GF Value of $1302.77.
4DMedical announces collaboration with GlaxoSmithKline
4DMedical has announced a new agreement with GlaxoSmithKline to deliver lung imaging analytics for pulmonary drug development and clinical research. The collaboration integrates with an established research data platform to provide advanced imaging biomarkers for assessing lung function. This partnership builds on an existing relationship with AstraZeneca, reinforcing the company's footprint in the pharmaceutical sector. The deal highlights growing interest in data-driven respiratory diagnostics and non-invasive lung scanning technology, despite recent share price volatility.
Sun Pharma acquires Organon for $11.75 billion amid biopharma M&A surge
On 27 April 2026, Sun Pharma announced an all-cash acquisition of Organon valued at $11.75 billion. The deal includes 70 products in women's health and general medicines, including biosimilars. This transaction occurs as the global biopharmaceutical industry faces a significant revenue decline due to the Patent Cliff, with over $200 billion in annual revenue at risk of loss of exclusivity in the US by the end of the decade. The acquisition aims to secure an established portfolio and bypass the R&D cycle.
GLP-1 agonists classified as biological medicines in EU and UK
GLP-1 receptor agonists are peptide-based medicines regulated as biological medicines in the EU, UK, and most ICH-aligned jurisdictions. In the US, the FDA classifies most as drugs under the Federal Food, Drug, and Cosmetic Act unless they meet statutory biological definitions. Injectable products with integral delivery devices are regulated as combination drug-device products. Manufacturers must verify jurisdiction-specific classifications before filing strategies to avoid delays.
UK mental health nurses describe workload as unmanageable amid patient harm risks
A Royal College of Nursing (RCN) survey reveals that specialist mental health nurses in the UK consider their workload unmanageable, with only one in five reporting manageable caseloads. The poll indicates that 51% of respondents believe patients are frequently harmed due to high caseloads and understaffing. Demand for community services rose by 38% between 2022 and 2025, while the nursing workforce grew by just 15%. The RCN calls for urgent investment, while the Department of Health and Social Care cites record funding and recruitment increases.
Researchers present rapid multiplex molecular diagnostic systems at ESCMID conference
Global researchers presented preliminary data on new rapid molecular test systems at the European Society of Clinical Microbiology and Infectious Diseases annual conference in New York. Companies including Cepheid, SD Biosensor, Qiagen, and Diasorin showcased assays for pathogen identification and antimicrobial resistance. Presentations highlighted real-world data on workflow efficiency, cost savings, and improved diagnostic yield for conditions like meningitis and respiratory infections. Novel chemistries using CRISPR and thermal-induced switching probes were also demonstrated as potential future developments for faster, cheaper testing.